Trial Profile
Overcoming Drug Resistance in Metastatic Castration-resistant Prostate Cancer With Novel Combination of TGF-β Receptor Inhibitor LY2157299 and Enzalutamide: a Randomized Multi-site Phase II Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2023
Price :
$35
*
At a glance
- Drugs Galunisertib (Primary) ; Enzalutamide
- Indications Prostate cancer
- Focus Therapeutic Use
- 05 Jun 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
- 05 Jun 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 01 Jun 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.